PubMed Health⌕ Search

Biomedical subjects

D M Chuang

Publications and source records attributed to D M Chuang.

At least 127 records · Page 7Linked to original sources

Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover.

The 5HT-mediated contraction of rat thoracic aorta is competitively blocked by the specific receptor antagonist 5HT2 ketanserin. In this tissue the addition of 5HT activated the turnover of 3H-phosphatidylinositol in a ketanserin-reversible fashion. These 5HT2 recognition sites appear to be coupled to a phospholipase C mediated cleavage of phosphatidylinositol.

Animals↗

Modulation by calcium of gamma-aminobutyric acid (GABA) binding to GABAA and GABAB recognition sites in rat brain. Involvement of different mechanisms.

Calcium modulates sodium-independent binding of gamma-aminobutyric acid (GABA) to GABAA and GABAB recognition sites located in synaptic membranes of rat brain. At 37 degrees the binding of [3H]GABA to the GABAB recognition site is dramatically stimulated by Ca2+ with an EC50 (half-saturation constant) of congruent to 10 microns, whereas the binding to the GABAA recognition site is only slightly, but significantly, potentiated by Ca2+ with an EC50 of congruent to 0.1-1.0 micron. The effect of calcium on GABAA recognition sites requires a temperature of 37 degrees and the presence of calmodulin. Only GABAA recognition sites are linked to benzodiazepine recognition sites, and the interaction between these sites is modulated by Ca2+ at physiological ion concentrations. When free Ca2+ in the assay medium is below 10 nM, only one population of low-affinity GABAA recognition sites can be measured; however, when free Ca2+ is at the micromolar level, or if diazepam is present, a high affinity-binding site appears in addition to the pre-existing low-affinity component. On the basis of affinity there is a single population of GABAB bindings sites, but the number of sites is about 90% greater at 37 degrees than at 4 degrees. This temperature-dependent increase in the number of GABAB recognition sites is calmodulin-independent, and data with leupeptin, hemin, and antipain suggest that this temperature-dependent increase in GABAB sites might involve the activity of Ca2+-dependent protease(s).

Animals↗

Daily bupropion injections for 3 weeks attenuate the NE stimulation of adenylate cyclase and the number of beta-adrenergic recognition sites in rat frontal cortex.

In rats receiving daily doses (50 mg/kg i.p. twice daily) of bupropion HCI (WellbutrinR) repeated for 21 days the Bmax of the beta-adrenergic receptor recognition sites located in the frontal cortex is reduced. This decrease is not associated with a decrease of the apparent affinity of these recognition sites. However the Vmax of the cAMP (cyclic AMP) generating system stimulated by NE is reduced suggesting that similarly to other antidepressants bupropion down regulates beta-adrenergic receptors located in the frontal cortex. Bupropion neither inhibits MAO (monoamine oxidase) nor releases biogenic amines but only weakly inhibits monoamine uptake in vitro.

Adenylyl Cyclases↗

On the mode of action of imipramine: relationship between serotonergic axon terminal function and down-regulation of beta-adrenergic receptors.

Recognition sites for [3H]imipramine and [3H]mianserin are located in different structures and regulate different neuronal functions. Recognition sites for [3H]imipramine are located on serotonergic terminals, are part of the supramolecular organization of the uptake mechanisms and can be down-regulated by prolonged administration of the drug. When the number of recognition sites for imipramine is down-regulated, uptake of 5-hydroxytryptamine (5HT) in rat brain hippocampal slices is increased. The presence of the binding sites for imipramine in 5HT terminals is essential to mediate the down-regulation of recognition sites for norepinephrine (NE) and NE-mediated stimulation of adenylate cyclase. Mianserin binds on a site that is modulated by 5HT, the number of its binding sites is not down-regulated by repeated treatment and, like imipramine, decreases the NE-dependent cyclase but not the number of beta-adrenergic receptor recognition sites. Repeated treatment with imipramine and mianserin down-regulated the number of 5HT2 recognition sites. Several lines of evidence indicate that binding site for mianserin is related but not identical to the 5HT2 receptor binding site.

Animals↗

Differences in the regulatory adaptation of the 5HT recognition sites labelled by 3H-mianserin or 3H-ketanserin.

In crude synaptic membranes prepared from rat brain the sites occupied by 3H-spiroperidol that are displaced by microM concentrations of serotonin (5HT) have been termed 5HT2 receptors (Peroutka and Snyder, 1980). Since the 3H-spiroperidol displaced by 5HT is also displaced very effectively (IC50 in the nM range) by ketanserin and mianserin it was suggested that spiroperidol, mianserin and ketanserin are labelling 5HT2 receptors. Data are presented showing that the 3H-ketanserin and 3H-mianserin bound to crude synaptic membrane in the presence of a H1 receptor blocker are not labelling the same recognition site. Hence from this standpoint the recognition site marked by 3H-mianserin and 3H-ketanserin is not identical. The possibility that allosteric effects are operative in some of these ligand displacements should be entertained.

Animals↗

Modulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine recognition sites.

Imipramine inhibits the serotonin uptake by binding with high affinity to regulatory sites of this uptake located on axons that release serotonin. The number of imipramine recognition sites located on crude synaptic membrane preparations is reduced by two daily injections of imipramine or desmethylimipramine for 3 weeks. When the binding sites for [3H]imipramine are down-regulated the Vmax of the neuronal uptake of serotonin is increased. Moreover, in minces prepared from the brain hippocampus of rats receiving imipramine in a dose regimen that reduces the number of [3H]imipramine recognition sites, the efficiency of imipramine as a blocker of the serotonin uptake is diminished. Hence the high-affinity binding sites for [3H]imipramine may have a physiological role in modulation of serotonin reuptake. Probably this is mediated by an endogenous effector of these regulatory sites. A nonpeptidic constituent of rat brain capable of displacing [3H]imipramine from its high-affinity binding site and of inhibiting the serotonin uptake in a dose-related manner has been extracted and its partial purification is described.

Animals↗

Serotonin-elicited amplification of adenylate cyclase activity in hippocampal membranes from adult rat.

The activity of the adenylate cyclase located in membranes prepared from hippocampus of adult rat can be stimulated by serotonin (5-HT) (Ka = 4 X 10(-7) M). The maximal effect is obtained with 10 microM 5-HT. Freezing of the tissue decreases the 5-HT stimulation; this stimulation is optimal in the presence of 82.5 mM Tris-maleate buffer (pH 7.4) and 50 microM GTP. The adenylate cyclase activity of membranes prepared from cortex, hypothalamus, and colliculi of adult rats is not significantly stimulated by 5-HT. Dopamine (DA) also stimulates adenylate cyclase located in hippocampal membranes; its effect can be blocked by haloperidol (10(-6) M), which fails to inhibit 5-HT stimulation. Moreover, p-chlorophenylalanine treatment for 2 weeks or selective lesion of 5-HT axons afferent to the hippocampus increases the Vmax of 5-HT stimulation, but fails to change that of DA stimulation. The 5-HT stimulation can be inhibited by metergoline, spiroperidol, and pizotyline (10(-6) M), but not by the same concentrations of mianserin, ketanserine, alprenolol, phenoxybenzamine, and mepyramine. The 5-HT stimulation of adenylate cyclase of hippocampal membranes can be mimicked by tryptamine, 5-methoxytryptamine, bufotenine, and to a lesser extent by LSD; N-methyltryptamine, N-methyltryptophan, and 5-hydroxytryptophan are inactive. Studies with kainic acid suggest that the 5-HT recognition site (5-HT1) linked to adenylate cyclase is located on the membrane of intrinsic hippocampal neurons.

Adenylyl Cyclases↗

Different synaptic location of mianserin and imipramine binding sites.

The high-affinity binding sites for mianserin and imipramine appear to be locate in different neurons of rat brain. Studies in which lesions were produced with 5,7-dihydroxytryptamine and other studies in which the 5-hydroxytryptamine content was decreased with p-chlorophenylalanine indicate that some of the imipramine binding sites are on serotonin axon terminals and others are on nonserotonergic synapses. The sites that bind mianserin are on postsynaptic serotonin sites as well as on synapses of other neuronal systems.

5,7-Dihydroxytryptamine↗

Down-regulation of beta-adrenergic receptors following repeated injections of desmethylimipramine: permissive role of serotonergic axons.

The injection of desmethylimipramine (DMI) twice daily for 3 weeks reduced the density of beta-adrenergic receptor recognition sites located in crude synaptic membranes prepared from the cortex and hippocampus and attenuated the stimulation of the membrane-bound adenylate cyclase by isoproterenol. Both actions were abolished if prior to treatment with desmethylimipramine the serotonergic axons were destroyed by an intraventricular injection of 5,7-dihydroxytryptamine. These results show that the down-regulation of beta-adrenergic receptors elicited by repeated injections of desmethylimipramine occurs only if the serotonergic axons are intact.

5,7-Dihydroxytryptamine↗

Inhibitors of transglutaminase prevent agonist-mediated internalization of beta-adrenergic receptors.

In frog erythrocytes, desensitization of beta-adrenergic receptors is characterized by a decrease in the beta-receptor recognition sites in the plasma membrane and a concomitant increase in the number of this receptor's binding sites in the cytosol. We have documented that this redistribution of the receptor recognition sites reflects the internalization of the surface-bound beta-adrenergic receptors. The present study was addressed to examine whether transglutaminase plays a role in the agonist-mediated internalization of beta-adrenergic receptor recognition sites. Pretreatment of cells with methylamine was found to decrease the internalization and the loss of membrane-bound beta-adrenergic receptors induced by isoproterenol. Methylamine appears to be equally potent in inhibiting transglutaminase activity and in preventing internalization and the receptor loss. The effect of methylamine on soluble and on membrane-bound beta-adrenergic receptors is due to a change in Bmax rather than Kd of these binding sites. Among eight inhibitors of transglutaminase tested, the rank order potency for blocking the enzyme can be correlated with that for preventing the receptor loss and receptor internalization. Moreover, these drug effects on beta-adrenergic receptors are unrelated to the inhibition of isoproterenol-sensitive adenylate cyclase or the binding of [3H]dihydroalprenolol to beta-receptors. These result may lend credence to the view that transglutaminase participates in the internalization and the decrease of membrane-bound receptors during desensitization of beta-adrenergic receptors.

Adrenergic beta-Agonists↗

Polypeptide hormones and chromatin-associated proteins act as acceptors for cholera toxin-catalyzed ADP-ribosylation.

Cholera toxin catalyzed the ADP-ribosylation of the pituitary protein hormones thyrotropin (TSH), lutropin (LH), follitropin (FSH), human chorionic gonadotropin (hCG), and corticotropin (ACTH)1-24, and ADP-ribosylation of the basic proteins histone subfraction H1 and protamine. Casein and phosvitin, acidic nuclear proteins, did not act as acceptors for toxin-catalyzed ADP-ribosylation. The isolated TSH A and B subunits were tested for their ADP-ribose acceptor activity. The TSH A subunit showed fourfold greater ADP-ribose acceptor activity than the TSH B subunit. The ADP-ribose acceptor protein protamine was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis following incubation with cholera toxin under ADP-ribosylating conditions. [3H]ADP-ribose incorporated into protein from [3H]NAD migrated with the acceptor protein protamine. In the absence of added acceptor protein, the [3H]ADP-ribose incorporated into protein migrated with the A1 fragment of cholera toxin. Cholera toxin A and B subunits were isolated and tested for their ability to catalyze the transfer of ADP-ribose to protamine. The cholera toxin A subunit showed 50-fold greater ADP-ribosyltransferase activity than the B subunit. Our data indicate that a variety of adenohypophyseal hormones and regulatory proteins act as acceptors for toxin-catalyzed ADP-ribosylation. These studies may help in understanding the role of endogenous ADP-ribosyltransferases and the physiological effects of this modification of protein.

Adenosine Diphosphate Ribose↗